


CONTENTS

| | | |
|---|---|--|
| Platinum Opinions |  | <p>The Platinum Hall of Fame e147 http://dx.doi.org/10.1016/j.eururo.2019.04.013</p> |
| |  | <p>Multiparametric Magnetic Resonance Imaging Before Prostate Biopsy: A Chain is Only as Strong as its Weakest Link 889 <i>O. Rouvière, I.G. Schoots, N. Mottet</i> Multiparametric magnetic resonance imaging (mpMRI) and MRI-guided biopsies play an important role in prostate cancer diagnosis, but further improvements are still needed. These should include reliable risk stratification for patients, better mpMRI inter-reader reproducibility and specificity, and definition of the cancers that need immediate diagnosis.</p> |
| |  | <p>Setting Research Priorities in Partnership with Patients to Provide Patient-centred Urological Cancer Care 891 <i>S.H. Rossi, A. Fielding, C. Blick, C. Handforth, J.E. Brown, G.D. Stewart</i> There is a well-documented discrepancy in prioritisation of research agendas between patients and researchers. Patient involvement in urological research from the outset is critical for well-prioritised research.</p> |
|  | <p>Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit 894 <i>A. Dalla Volta, A.M. Formenti, A. Berruti</i> Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.</p> | |
| Brief Correspondence |  | <p>External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort 896 <i>D. Tilki, F. Preisser, M. Graefen, H. Huland, R.S. Pompe</i> Our findings corroborate the validity of the novel European Association of Urology biochemical recurrence risk grouping, which is easily applicable in daily practice and could be valuable in decision-making for salvage therapy and clinical trials.</p> |
| |  | <p>askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men 901 <i>G.B. Auffenberg, K.R. Ghani, S. Ramani, E. Usoro, B. Denton, C. Rogers, B. Stockton, D.C. Miller, K. Singh</i> We have developed and tested a tool to help men newly diagnosed with prostate cancer to view predicted treatment decisions based on similar patients from our registry. We have made this tool available online for patient use.</p> |
| Platinum Priorities |  | <p>Patient Decision-making: Where Are We Going? 908 <i>P.C. Albertsen</i></p> |

Original Articles and Brief Correspondence together with the Full Length Editorials

Prostate Cancer

| | |
|--|--------------------|
| <p>Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer</p> <p><i>N.J. Sathianathan, B.R. Konety, F. Alarid-Escudero, N. Lawrentschuk, D.M. Bolton, K.M. Kuntz</i></p> <p>Active surveillance outcomes and costs can be optimized by decreasing the intensity of follow-up testing and potentially using multiparametric magnetic resonance imaging—if the cost is similar to the Medicare reimbursement rate—to determine which patients require biopsy.</p> | <p>EU★ACME 910</p> |
| <p>Optimizing Prostate Cancer Surveillance: Using Data-driven Models for Informed Decision-making</p> <p><i>B.T. Denton, S.T. Hawley, T.M. Morgan</i></p> | 918 |
| <p>Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer</p> <p><i>M.M. Heck, R. Tauber, S. Schwaiger, M. Retz, C. D'Alessandria, T. Maurer, A. Gafita, H.-J. Wester, J.E. Gschwend, W.A. Weber, M. Schwaiger, K. Knorr, M. Eiber</i></p> <p>Radioligand therapy with ¹⁷⁷Lu-PSMA-I&T showed good activity in more than one-third of patients with late-stage metastatic castration-resistant prostate cancer at low toxicity. Presence of visceral metastases and rising lactate dehydrogenase were associated with worse treatment outcome.</p> | <p>EU★ACME 920</p> |
| <p>Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics</p> <p><i>D.G. Murphy, A.A. Azad, S. Sandhu, J. Violet, M.S. Hofman</i></p> | 927 |
| <p>Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint</p> <p><i>E.M. Basch, M. Scholz, J.S. de Bono, N. Vogelzang, P. de Souza, G. Marx, U. Vaishampayan, S. George, J.K. Schwarz, E.S. Antonarakis, J.M. O'Sullivan, A.R. Kalebastiy, K.N. Chi, R. Dreicer, T.E. Hutson, A.C. Dueck, A.V. Bennett, E. Dayan, M. Mangeshkar, J. Holland, A.L. Weitzman, H.I. Scher</i></p> <p>Control of debilitating pain is an unmet need for men with metastatic castration-resistant prostate cancer (mCRPC). This phase 3 trial failed to show an improved pain response for cabozantinib compared with mitoxantrone-prednisone in patients with previously treated, symptomatic mCRPC.</p> | 929 |
| <p>Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2</p> <p><i>P.B. Østergren, T.J. Murtola, M. Fode</i></p> | 938 |
| <p>Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial</p> <p><i>D.J. Khalaf, K. Sunderland, B.J. Eigel, C.K. Kollmannsberger, N. Ivanov, D.L. Finch, O. Oja, J. Vergidis, M. Zulfiqar, M.E. Gleave, K.N. Chi</i></p> <p>In a phase II randomized trial of abiraterone versus enzalutamide for metastatic prostate cancer, men aged ≥75 yr who were treated with abiraterone had better quality of life. Abiraterone was associated with better physical well-being, prostate cancer symptom, and depression scores.</p> | 940 |
| <p>Hard Problems Need “Soft” Science: Integrating Quality of Life into Treatment Decision Making</p> <p><i>A.K. Morgans, C.J. Ryan</i></p> | 948 |
| <p>Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer</p> <p><i>S.A. Kenfield, E.L. Van Blarigan, N. Ameli, E. Lavaki, B. Cedars, A.T. Paciorek, C. Monroy, L.K. Tantum, R.U. Newton, C. Signorelli, J.H. Suh, L. Zhang, M.R. Cooperberg, P.R. Carroll, J.M. Chan</i></p> | 950 |

| | |
|-------------------------------|---|
| | <p>Tailored print materials combined with technology integration, including the use of a website, text messaging, and physical activity trackers, helped men with prostate cancer adopt healthy lifestyle habits, in particular recommended dietary changes, in the Prostate 8 pilot trial.</p> <p>Effective Technology-based Behaviour Change Interventions in Prostate Cancer Supportive Care: Are We There Yet? 959</p> <p><i>C.E. Short, L. Trinh, E.L. James</i></p> |
| Bladder Cancer | <p>The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability 961</p> <p><i>J. Kim, D. Kwiatkowski, D.J. McConkey, J.J. Meeks, S.S. Freeman, J. Bellmunt, G. Getz, S.P. Lerner</i></p> <p>We describe a novel single-patient classifier based on The Cancer Genome Atlas 2017 scheme that identified the neuronal subtype of urothelial carcinoma as an extreme responder to anti-PD-L1 therapy. In the future, trials targeting subtype-based therapy may improve precision delivery of care for urothelial carcinoma.</p> <p>Personalised Medicine for Advanced Urothelial Cancer: What is the Right Way to Identify the Right Patient for the Right Treatment? 965</p> <p><i>S.J. Crabb</i></p> |
| Reviews | <p>Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review 967</p> <p><i>T. Van den Broeck, R.C.N. van den Bergh, N. Arfi, T. Gross, L. Moris, E. Briers, M. Cumberbatch, M. De Santis, D. Tilki, S. Fanti, N. Fossati, S. Gillissen, J.P. Grummet, A.M. Henry, M. Lardas, M. Liew, O. Rouvière, J. Pecanka, M.D. Mason, I.G. Schoots, T.H. van Der Kwast, H.G. van Der Poel, T. Wiegel, P.-P.M. Willemsse, Y. Yuan, T.B. Lam, P. Cornford, N. Mottet</i></p> <p>In patients who underwent radical prostatectomy as primary treatment and who subsequently developed biochemical recurrence (BCR), the main prognostic factor for distant metastases, prostate cancer-specific mortality, and overall mortality is short prostate-specific antigen doubling time (ie, <1 yr), and to a lesser extent an increasing pathological Gleason score (GS) and a short interval to biochemical failure (IBF). The main prognostic factors for patients developing BCR following primary radiotherapy are a short IBF (<18 mo) and to a lesser extent an increasing biopsy GS.</p> |
| Prostate Cancer | <p>A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment  988</p> <p><i>B. Peyronnet, E. Mironska, C. Chapple, L. Cardozo, M. Oelke, R. Dmochowski, G. Amarenco, X. Gamé, R. Kirby, F. Van Der Aa, J.-N. Cornu</i></p> <p>There is a temptation to label overactive bladder (OAB) as “idiopathic” without obvious causation as “idiopathic”, given the poorly understood nature of its pathophysiology. However, OAB should be seen as a complex multifactorial syndrome, resulting from multiple potential pathophysiological mechanisms. Identification of the underlying causes on an individual basis may lead to the definition of OAB phenotypes, paving the way for personalised medical care.</p> |
| Female Urology – Incontinence | <p>Lifelong Congenital Urology: The Challenges for Patients and Surgeons 1001</p> <p><i>D. Wood, A. Baird, L. Carmignani, G. De Win, P. Hoebeke, G. Holmdahl, G. Manzoni, R.J.M. Nijman, C. Taylor, S. Tekgul</i></p> <p>Congenital urology is a fascinating field involving the lifelong care of patients with congenital anomalies. We provide a current position statement from which a network of interested practitioners will be able to build further.</p> |
| Reconstructive Urology | <p>“Ride the Green Light”: Indocyanine Green-marked Off-clamp Robotic Partial Nephrectomy for Totally Endophytic Renal Masses 1008</p> <p><i>G. Simone, G. Tuderti, U. Anceschi, M. Ferriero, M. Costantini, F. Minisola, G. Vallati, G. Pizzi, S. Guaglianone, L. Misuraca, M. Gallucci</i></p> <p>According to our preliminary experience, off-clamp robot-assisted partial nephrectomy after preoperative superselective indocyanine green tumor marking appeared to be a safe and effective procedure for the surgical treatment of totally endophytic renal tumors, achieving full trifecta outcomes and excellent functional results. Further prospective studies are awaited.</p> |
| Surgery in Motion | |

| | | |
|--|---|--|
| Original Articles |  | <p>Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer? 1015</p> <p><i>S.V. Carlsson, M. Månsson, S. Moss, M. Kwiatkowski, F. Recker, T.L.J. Tammela, C. Bangma, M.J. Roobol, A. Auvinen, J. Hugosson</i></p> <p>The reduction in prostate cancer mortality in the European Randomized Study of Screening for Prostate Cancer (ERSPC) is a result of early detection and not differential treatment between trial arms.</p> |
| Prostate Cancer |  | <p>The ERUS Curriculum for Robot-assisted Partial Nephrectomy: Structure Definition and Pilot Clinical Validation 1023</p> <p><i>A. Larcher, G. De Naeyer, F. Turri, P. Dell'Oglio, U. Capitanio, J.W. Collins, P. Wiklund, H. Van Der-Poel, F. Montorsi, A. Mottrie</i></p> <p>The European Association of Urology (EAU) Robotic Urology Section curriculum for robot-assisted partial nephrectomy can protect patients from suboptimal outcome during the learning curve and can aid surgeons willing to start a robot-assisted partial nephrectomy (RAPN) program. The curriculum is safe, because it does not result in any detriment to patient's clinical outcomes and is effective, as allows the transition from the beginning of surgical experience through increasing responsibility to the independent completion of a full case.</p> |
| Kidney Cancer |  | <p>Re: Financial Conflicts of Interest Among Authors of Urology Clinical Practice Guidelines 1032</p> <p><i>P. Dahm, S. Sultan</i></p> <p>Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712—A Randomized Phase II Trial 1033</p> <p><i>J.A. Witjes</i></p> <p>Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer 1034</p> <p><i>V.M. Narayan, A.H. Lim, C.P.N. Dinney</i></p> <p>Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years 1035</p> <p><i>R.J. Karnes, G. Motterle</i></p> <p>Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer—29-Year Follow-up 1036</p> <p><i>L. Hofer, M. Hohenfellner</i></p> <p>Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men 1036</p> <p><i>C.J.D. Wallis, L. Klotz, Z. Klaassen</i></p> |
| Words of Wisdom |  | <p>Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores 1038</p> <p><i>B.A. Mahal, M. Alshalalfa, D.E. Spratt, E. Davicioni, S.G. Zhao, F.Y. Feng, T.R. Rebbeck, P.L. Nguyen, F.W. Huang</i></p> <p>Patterns of Knowledge Acquisition Among Men Undergoing Radical Prostatectomy 1040</p> <p><i>M. Fode, A. Frey, P.B. Østergren, C.F. Jensen, J. Sønksen</i></p> |
| Research Letters |  | <p>Re: Alberto Briganti, Nicola Fossati, James W.F. Catto, et al. Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:357–68 e155</p> <p><i>Y. Wei, T. Li, L. Liu</i></p> <p>Re: Mark Douglas Tyson II, Tatsuki Koyama, Dan Lee, et al. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol 2018;74:26–33 e157</p> <p><i>A. Gokce, D. Gul</i></p> |
| Letters to the Editor published online |  | |

- Re: Peter K.-F. Chiu, Chi-Fai Ng, Axel Semjonow, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. *Eur Urol* 2019;75:558–61 e158
I. Heidegger, R. Pichler
- Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. *Eur Urol*. In press. 2019;75:538–40 e160
M. Rijnders, A.A.M. van der Veldt, R. de Wit, G.J.L.H. van Leenders
- Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. *Eur Urol*. In press. 2019;75:538–40 e162
T. Gevaert, M. Eckstein, R. Montironi, A. Lopez-Beltran
- Re: Timu J. Murtola, Hemo Syväälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy—A Randomized, Double-blind, Placebo-controlled Clinical Trial. *Eur Urol* 2018;74:697–701 e164
J.H. Kim, B.I. Chung
- Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syväälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy—A Randomized, Double-blind, Placebo-controlled Clinical Trial. *Eur Urol* 2018;74:697–701 e166
T.J. Murtola, H. Syväälä, J. Riikonen
- Re: Rano Matta, Christopher J.D. Wallis, Mitchell G. Goldenberg, et al. Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. *Eur Urol* 2019;75:3–7. Translational Potential of Dual Detection: Depression Diagnosis plus Sense of Coherence Determination in Prostate Cancer A Population-based Cohort Study. *Eur Urol* 2019;75:3–7 e168
S. Vale
- Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? *Eur Urol*. 2019;75:602–3 e170
M.R. Goldstein, L. Mascitelli
- Re: Guido Giusti, Silvia Proietti, Moises E. Rodríguez-Socarrás, et al. Simultaneous Bilateral Endoscopic Surgery (SBES) for Patients with Bilateral Upper Tract Urolithiasis: Technique and Outcomes. *Eur Urol* 2018;74:810–5 e171
L. Boeri, E. Montanari
- Reply to Luca Boeri and Emanuele Montanari's Letter to the Editor re: Guido Giusti, Silvia Proietti, Moises E. Rodríguez-Socarrás, et al. Simultaneous Bilateral Endoscopic Surgery (SBES) for Patients with Bilateral Upper Tract Urolithiasis: Technique and Outcomes. *Eur Urol* 2018;74:810–5 e173
G. Giusti, S. Proietti, M.E. Rodríguez-Socarrás, B.H. Eisner
- Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. *Eur Urol* 2019;75:853–60 e175
R. Pichler, I. Heidegger
- Reply to Maxine G. Tran, Ravi Barod, and Axel Bex's Letter to the Editor re: Philip S. Macklin, Mark E. Sullivan, Charles R. Tapping, et al. Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. *Eur Urol* 2019;75:861–7 e177
P.S. Macklin, M.E. Sullivan, C.R. Tapping, G.M. Webster, I.S.D. Roberts, C.L. Verrill, L. Browning

Re: Philip S. Macklin, Mark E. Sullivan, Charles R. Tapping, et al. Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. *Eur Urol*. Eur Urol 2019;75:861–7 e179

M.G.B. Tran, R. Barod, A. Bex

Congress Calendar e181

Acknowledgement to Reviewers e186

The illustration on the cover of this issue is taken from the article by Jaegil Kim, David Kwiatkowski, David J. McConkey, Joshua J. Meeks, Samuel S. Freeman, Joaquim Bellmunt, Gad Getz, Seth P. Lerner, The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability, which is published on pp. 961–964 of this issue.v

